Scholar Rock to Showcase Neuromuscular Research Portfolio at 2026 Annual Cure SMA Research and Clinical Care Meeting and 2026 International Research Congress on FSHD
Scholar Rock announced it will present updates on its neuromuscular portfolio at the upcoming Cure SMA and FSHD Society conferences in late June. Presentations will include post hoc analyses from the Phase 3 SAPPHIRE trial of apitegromab in SMA and design details for the Phase 2 FORGE study in FSHD.
Key figures
- Drug Name
- Apitegromab
- Phase Of Trial
- Phase 3
- Trial name sma
- SAPPHIRE
- Trial name fshd
- FORGE
- Secondary trial phase
- Phase 2
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.